Brief: Vor Bio Announces Oral Presentation Of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study
17/09/2025 21:32
Sept 17 (Reuters) - Vor Biopharma Inc VOR.O: VOR BIO ANNOUNCES ORAL PRESENTATION OF 48-WEEK CHINA PHASE 3 GENERALIZED MYASTHENIA GRAVIS CLINICAL STUDY AT AANEM Source text: ID:nGNX5NPlMf Further company coverage: VOR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vor Biopharma
See all newsBrief: Telitacicept Demonstrates Durable Preservation Of Kidney Function Through Two Years In Phase 3 Teligan Trial In Iga Nephropathy
Vor Bio says its experimental drug slowed loss of kidney function in late-stage study
U.S. STOCKS ON THE MOVE-Vor Biopharma, Fair Isaac Corp, Plug Power
U.S. STOCKS ON THE MOVE-Snowflake, Cboe, Oracle
US STOCKS ON THE MOVE-Veracyte, Staar Surgical, Corning